

Erratum to: Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML)

Elisabetta Abruzzese · Massimo Breccia ·
Roberto Latagliata

Published online: 22 March 2014
© Springer International Publishing Switzerland 2014

Erratum to: BioDrugs
DOI 10.1007/s40259-013-0056-z

The authors have alerted us to the following error:

Page 7, section 3.5, 3rd paragraph, lines 10–15: The following phrase which reads:

“Porkka et al. [54] showed that the incidence of pleural effusions was significantly reduced with dasatinib 100 mg four times daily compared with dasatinib 50 mg, 70 mg bid or 140 mg QD (14 % vs. 23–26 %, respectively) over a 24-month minimum follow-up.”

should read:

“Porkka et al. [54] showed that the incidence of pleural effusions was significantly reduced with dasatinib 100 mg once daily compared with dasatinib 50 mg, 70 mg bid or 140 mg QD (14 % vs. 23–26 %, respectively) over a 24-month minimum follow-up.”

The online version of the original article can be found under
doi:[10.1007/s40259-013-0056-z](https://doi.org/10.1007/s40259-013-0056-z).

E. Abruzzese (✉)
Hematology, S. Eugenio Hospital, Tor Vergata University,
P. le dell'Umanesimo 10, 00144 Rome, Italy
e-mail: elisabetta.abruzzo@uniroma2.it

M. Breccia
Department of Cellular Biotechnology and Hematology,
Sapienza University, Rome, Italy
e-mail: breccia@bce.uniroma1.it

R. Latagliata
Department of Cellular Biotechnologies and Hematology,
Sapienza University of Rome, Via Benevento 6, Rome, Italy
e-mail: rob.lati@libero.it